Michael P. Chrissoheris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael P. Chrissoheris has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Konstantinos Papadopoulos
Echocardiography Department Interbalkan Medical Center Thessaloniki Greece
4 shared publications Konstantinos Spargias
Department of Transcatheter Heart Valves, Hygeia Hospital , 9 Erythrou Stavrou Street , Marousi, TK 15123 Attiki, Greece
4 shared publications- Vlasis Ninios
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
3 shared publications Antonios Halapas
From the Department of Transcatheter Heart Valves, HYGEIA Hospital, Athens, Greece
2 shared publicationsPanagiota Kourkoveli
Department of Transcatheter Heart Valves, Hygeia Hospital , 9 Erythrou Stavrou Street , Marousi, TK 15123 Attiki, Greece
2 shared publicationsAdamantios Tsangaris
Hygeia Hospital, Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 18 June 2024
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 80, 64-82
Transoesophageal echocardiography beyond the echo-laboratory. An expert consensus paper of the working group of echocardiography of the hellenic society of cardiology
- 18 June 2024
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 80, 64-82
Open AccessTransoesophageal echocardiography beyond the echo-laboratory. An expert consensus paper of the working group of echocardiography of the hellenic society of cardiology
- Open Access
- 30 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (2) , ytae041
Severe functional ischaemic mitral regurgitation: is functional a misnomer for a dysfunctional valve? A case report
Background: Mitral regurgitation (MR) in the context of left ventricular systolic dysfunction is often designated as functional, with emphasis on the underlying cardiomyopathy leading to malcoaptation of the ‘otherwise normal valve’. Case summary: A 63-year-old male with ischaemic cardiomyopathy (left ventricular ejection fraction 20%) presented with intractable heart failure in need of inotropic support and could not be stepped down from an ICU hospital setting. Functional MR, graded as moderate on transthoracic echocardiography, was initially not considered as pertinent to the clinical condition and options discussed included initiation of dialysis for volume management, chronic inotropic support, and palliative measures. However, a re-examination of the mitral valve by transoesophageal echo revealed severe regurgitation from annular dilatation and restricted mobility during systole. Transcatheter edge to edge repair utilizing the PASCAL device resulted in marked reduction of MR followed by an abrupt clinical improvement, weaning off inotropes and discharge home 4 days later. At four-year follow-up, the patient is stable on optimal heart failure therapy. Discussion: For many patients with heart failure and underlying cardiomyopathy, the presence of significant functional MR, instead of a ‘bystander’ disease, actually becomes the dominant driver of symptoms and compounds the low cardiac output state. In these patients, the term ‘functional’ MR becomes a misnomer, as in fact the so called ‘otherwise normal’ mitral valve is actually a severely dysfunctional valve with a wide malcoaptation zone. Transcatheter edge to edge repair is an effective bailout procedure for patients with low cardiac output and disproportionate severe functional MR.
- 30 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (2) , ytae041
Open AccessSevere functional ischaemic mitral regurgitation: is functional a misnomer for a dysfunctional valve? A case report
Background: Mitral regurgitation (MR) in the context of left ventricular systolic dysfunction is often designated as functional, with emphasis on the underlying cardiomyopathy leading to malcoaptation of the ‘otherwise normal valve’. Case summary: A 63-year-old male with ischaemic cardiomyopathy (left ventricular ejection fraction 20%) presented with intractable heart failure in need of inotropic support and could not be stepped down from an ICU hospital setting. Functional MR, graded as moderate on transthoracic echocardiography, was initially not considered as pertinent to the clinical condition and options discussed included initiation of dialysis for volume management, chronic inotropic support, and palliative measures. However, a re-examination of the mitral valve by transoesophageal echo revealed severe regurgitation from annular dilatation and restricted mobility during systole. Transcatheter edge to edge repair utilizing the PASCAL device resulted in marked reduction of MR followed by an abrupt clinical improvement, weaning off inotropes and discharge home 4 days later. At four-year follow-up, the patient is stable on optimal heart failure therapy. Discussion: For many patients with heart failure and underlying cardiomyopathy, the presence of significant functional MR, instead of a ‘bystander’ disease, actually becomes the dominant driver of symptoms and compounds the low cardiac output state. In these patients, the term ‘functional’ MR becomes a misnomer, as in fact the so called ‘otherwise normal’ mitral valve is actually a severely dysfunctional valve with a wide malcoaptation zone. Transcatheter edge to edge repair is an effective bailout procedure for patients with low cardiac output and disproportionate severe functional MR.
- Open Access
- 14 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (12) , 4047
Correlation of Clinical Outcomes with the Prominent Indication of Transcatheter Paravalvular Leak Closure: A Multicenter Experience
Background: A paravalvular leak (PVL) is a complication following valve replacement, which may lead to heart failure and hemolysis. The aim of this study is to investigate whether the clinical outcome after transcatheter PVL closure differs according to the prominent indication of the procedure (symptoms of heart failure or hemolysis). Methods: The data of consecutive patients who had transcatheter treatment for PVL between July 2011 and September 2022 in five Greek centers were analyzed. The primary endpoint was the technical, and clinical success rates with regards to the prominent indication of paravalvular leak closure. The secondary endpoints included the evaluation and comparison of the clinical and technical success in relation to the type of valve that was treated (aortic or mitral) as well as the survival analysis in relation to the closure indication and type of valve that was treated. Results: In total, 60 patients were retrospectively studied (39% men, mean age 69.5 ± 11 years). Regarding the primary outcomes, the technical success in patients mainly suffering from hemolysis was 86.1%, while in those presenting heart failure it was 95.8%, p = 0.387. Furthermore, the clinical success was 72.2% and 87.5% among hemolysis and heart failure patients, respectively, p = 0.210. During the follow-up period, the two-year survival rates were significantly better for patients treated for the aortic valve (78.94%) compared to those in the mitral position (48.78%), p = 0.014. In total, 25 patients died (41.7%) during 24 months of follow-up. Conclusions: Transcatheter paravalvular leak closure can be performed with high technical and clinical success rates without any difference according to the prominent indication of closure.
- 14 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (12) , 4047
Open AccessCorrelation of Clinical Outcomes with the Prominent Indication of Transcatheter Paravalvular Leak Closure: A Multicenter Experience
Background: A paravalvular leak (PVL) is a complication following valve replacement, which may lead to heart failure and hemolysis. The aim of this study is to investigate whether the clinical outcome after transcatheter PVL closure differs according to the prominent indication of the procedure (symptoms of heart failure or hemolysis). Methods: The data of consecutive patients who had transcatheter treatment for PVL between July 2011 and September 2022 in five Greek centers were analyzed. The primary endpoint was the technical, and clinical success rates with regards to the prominent indication of paravalvular leak closure. The secondary endpoints included the evaluation and comparison of the clinical and technical success in relation to the type of valve that was treated (aortic or mitral) as well as the survival analysis in relation to the closure indication and type of valve that was treated. Results: In total, 60 patients were retrospectively studied (39% men, mean age 69.5 ± 11 years). Regarding the primary outcomes, the technical success in patients mainly suffering from hemolysis was 86.1%, while in those presenting heart failure it was 95.8%, p = 0.387. Furthermore, the clinical success was 72.2% and 87.5% among hemolysis and heart failure patients, respectively, p = 0.210. During the follow-up period, the two-year survival rates were significantly better for patients treated for the aortic valve (78.94%) compared to those in the mitral position (48.78%), p = 0.014. In total, 25 patients died (41.7%) during 24 months of follow-up. Conclusions: Transcatheter paravalvular leak closure can be performed with high technical and clinical success rates without any difference according to the prominent indication of closure.
- Open Access
- 22 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 1819
Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction
Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased risk of mortality. Transcatheter mitral valve repair may therefore be a suitable therapy. However, data on clinical outcomes of patients in an acute setting are scarce, especially those with reduced left ventricle (LV) dysfunction. We conducted a multinational, collaborative data analysis from 21 centers for patients who were, within 90 days of acute MI, treated with MitraClip due to severe MR. The cohort was divided according to median left ventricle ejection fraction (LVEF)—35%. Included in the study were 105 patients. The mean age was 71 ± 10 years. Patients in the LVEF < 35% group were younger but with comparable Euroscore II, multivessel coronary artery disease, prior MI and coronary artery bypass graft surgery. Procedure time was comparable and acute success rate was high in both groups (94% vs. 90%, p = 0.728). MR grade was significantly reduced in both groups along with an immediate reduction in left atrial V-wave, pulmonary artery pressure and improvement in New York Heart Association (NYHA) class. In-hospital and 1-year mortality rates were not significantly different between the two groups (11% vs. 7%, p = 0.51 and 19% vs. 12%, p = 0.49) and neither was the 3-month re-hospitalization rate. In conclusion, MitraClip intervention in patients with acute severe functional mitral regurgitation (FMR) due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.
- 22 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 1819
Open AccessSafety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction
Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased risk of mortality. Transcatheter mitral valve repair may therefore be a suitable therapy. However, data on clinical outcomes of patients in an acute setting are scarce, especially those with reduced left ventricle (LV) dysfunction. We conducted a multinational, collaborative data analysis from 21 centers for patients who were, within 90 days of acute MI, treated with MitraClip due to severe MR. The cohort was divided according to median left ventricle ejection fraction (LVEF)—35%. Included in the study were 105 patients. The mean age was 71 ± 10 years. Patients in the LVEF < 35% group were younger but with comparable Euroscore II, multivessel coronary artery disease, prior MI and coronary artery bypass graft surgery. Procedure time was comparable and acute success rate was high in both groups (94% vs. 90%, p = 0.728). MR grade was significantly reduced in both groups along with an immediate reduction in left atrial V-wave, pulmonary artery pressure and improvement in New York Heart Association (NYHA) class. In-hospital and 1-year mortality rates were not significantly different between the two groups (11% vs. 7%, p = 0.51 and 19% vs. 12%, p = 0.49) and neither was the 3-month re-hospitalization rate. In conclusion, MitraClip intervention in patients with acute severe functional mitral regurgitation (FMR) due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.
- Open Access
- 1 March 2020
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 61 (2) , 135-136
Transcatheter mitral valve-in-ring implantation by the transfemoral approach: First experience in Greece
- 1 March 2020
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 61 (2) , 135-136
Open AccessTranscatheter mitral valve-in-ring implantation by the transfemoral approach: First experience in Greece
- 27 November 2017
- Published by Springer Nature in Journal of Echocardiography
- Vol. 16 (2) , 91-92
Transcatheter MitraClip implantation facilitated by transthoracic echocardiography
- 27 November 2017
- Published by Springer Nature in Journal of Echocardiography
- Vol. 16 (2) , 91-92
Transcatheter MitraClip implantation facilitated by transthoracic echocardiography
- 5 May 2016
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 5 (3) , 257-263
Transcatheter aortic valve replacement in patients with prior chest irradiation and severe aortic stenosis
- 5 May 2016
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 5 (3) , 257-263
Transcatheter aortic valve replacement in patients with prior chest irradiation and severe aortic stenosis
- 13 August 2012
- Published by Springer Nature
- p. 83-91
Balloon Aortic Valvuloplasty
- 1 December 2011
- Vol. 23 (12) , E291-2
Early prosthetic valve endocarditis complicating repeated attempts at CoreValve implantation.
Transcatheter aortic valve implantation is emerging as a promising, effective therapy for high-risk patients not eligible to undergo surgical aortic valve replacement. Infection complications have only rarely been reported. We report a case of probable endocarditis caused by coagulase-negative Staphylococcus following repeated attempts at implantation of a CoreValve bioprosthesis.
- 1 December 2011
- Vol. 23 (12) , E291-2
Early prosthetic valve endocarditis complicating repeated attempts at CoreValve implantation.
Transcatheter aortic valve implantation is emerging as a promising, effective therapy for high-risk patients not eligible to undergo surgical aortic valve replacement. Infection complications have only rarely been reported. We report a case of probable endocarditis caused by coagulase-negative Staphylococcus following repeated attempts at implantation of a CoreValve bioprosthesis.